Pomerantz Law Firm Investigates ImmunityBio Investor Claims

The law firm is looking into potential legal issues on behalf of the company's shareholders.

Published on Feb. 20, 2026

Got story updates? Submit your updates here. ›

Pomerantz LLP, a prominent law firm, has announced that it is investigating potential claims on behalf of investors of ImmunityBio, a biopharmaceutical company. The investigation is focused on evaluating whether ImmunityBio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Why it matters

Investor lawsuits can have significant implications for public companies, potentially leading to financial penalties, legal settlements, and reputational damage. The outcome of this investigation could impact ImmunityBio's standing and operations.

The details

The Pomerantz law firm is conducting the investigation to determine if there have been any violations of federal securities laws by ImmunityBio and its leadership. This comes after the company has faced various challenges, including regulatory setbacks and questions about its financial reporting.

  • The investigation was announced on February 17, 2026.

The players

Pomerantz LLP

A prominent law firm that specializes in representing investors in securities fraud class actions and shareholder derivative litigation.

ImmunityBio

A biopharmaceutical company focused on developing innovative therapies for cancer and infectious diseases.

Got photos? Submit your photos here. ›

The takeaway

This investigation highlights the importance of transparency and accountability for public companies, as investor lawsuits can significantly impact a firm's operations and reputation. The outcome of this case will be closely watched by the biotech industry and the investment community.